title: Sorafenib: atypical cutaneous side effects.
authors.affiliation: Policlinico Umberto, Viale del Policlinico, 155 - 00161, Rome, Italy. antoniorichetta@hotmail.com
authors.forename: Antonio Giovanni
authors.initials: AG
authors.lastname: Richetta
authors.forename: Elisa
authors.initials: E
authors.lastname: Maiani
authors.forename: Valentina
authors.initials: V
authors.lastname: Carboni
authors.forename: Valentina
authors.initials: V
authors.lastname: Carlomagno
authors.forename: Manuella
authors.initials: M
authors.lastname: Cimillo
authors.forename: Carlo
authors.initials: C
authors.lastname: Mattozzi
authors.forename: Stefano
authors.initials: S
authors.lastname: Calvieri
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001557:Benzenesulfonates / Q000009:adverse effects*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy; D003875:Drug Eruptions / Q000209:etiology* / Q000473:pathology; D006801:Humans; D020930:MAP Kinase Kinase Kinases / Q000037:antagonists & inhibitors; D008297:Male; D009362:Neoplasm Metastasis / Q000188:drug therapy; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D011725:Pyridines / Q000009:adverse effects*; D012872:Skin Diseases, Vesiculobullous / Q000139:chemically induced* / Q000473:pathology; D000077157:Sorafenib
chemical_list: D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib; D020930:MAP Kinase Kinase Kinases